Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance

Acquired resistance to osimertinib is inevitable and heterogeneous despite its documented efficacy against EGFR‐mutated non‐small cell lung cancer (NSCLC). Subsequent therapeutic options assume the dominant form of the resistance mechanism; however, the more rare oncogenic driver, NTRK1 fusion, has...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jiao‐Li, Wang, Liu‐sheng, Zhu, Jun‐qi, Ren, Jie, Wang, Di, Luo, Man
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574602/
https://www.ncbi.nlm.nih.gov/pubmed/36258694
http://dx.doi.org/10.1002/rcr2.1054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574602/
https://www.ncbi.nlm.nih.gov/pubmed/36258694
http://dx.doi.org/10.1002/rcr2.1054

Ejemplares similares